Divi's Laboratories Limited

DIVISLAB

INE361B01024

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:49:39 2025-06-20 am EDT			5-day change	1st Jan Change
6,592.00 ^INR	+1.52%		-1.12%	+8.09%

May. 26	INDIA STOCKS-Indian shares advance on EU tariff relief, central bank's record dividend	RE
May. 19	INDIA STOCKS-Indian benchmark indexes drop as US downgrade hits IT stocks; broader market up on rate cut hopes	RE

Divi's Laboratories Posts Gains in Fiscal Q4 Consolidated Profit; Shares up 5%

Published on 05/19/2025 at 00:51

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Divi's Laboratories Limited

INDIA STOCKS-Indian shares advance on EU tariff relief, central bank's record dividend	May. 26	RE
INDIA STOCKS-Indian benchmark indexes drop as US downgrade hits IT stocks; broader market up on rate cut hopes	May. 19	RE
Jefferies Adjusts Divi's Laboratories' Price Target to INR6,200 From INR6,280, Keeps at Hold	May. 19	MT
INDIA STOCKS-India's equity benchmarks flat as IT shares offset wider gains	May. 19	RE
Divi's Laboratories Limited, Q4 2025 Earnings Call, May 17, 2025	May. 17
Divi's Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2025	May. 17	CI
Divi's Laboratories Limited Announces Executive Changes, Effective August 01, 2025	May. 17	CI
Divi's Laboratories Limited Announces Chief Financial Officer Changes, Effective August 01, 2025	May. 17	CI
Indian pharma stocks fall as Trump moves to cut U.S. drug prices	May. 12	RE
INDIA STOCKS-Indian equity benchmarks snap winning run on risk-off after Kashmir attack	Apr. 24	RE
Trump Skipping Pharma Tariffs Bouys Sector Stocks in India	Apr. 03	DJ
INDIA STOCKS-Indian shares buck global trade war fears to log best day in a month	Feb. 04	RE
Divi's Laboratories Posts Gains in Fiscal Q3 Consolidated Profit	Feb. 04	MT
INDIA STOCKS-Indian shares breathe a sigh of relief on US tariffs pause	Feb. 04	RE
INDIA STOCKS-Indian shares tumble as trade war shockwaves reach Mumbai	Feb. 03	RE
Divi's Laboratories Limited, Q3 2025 Earnings Call, Feb 03, 2025	Feb. 03
India's Divi's Labs beats Q3 profit estimates on strong API demand; shares rise	Feb. 03	RE
India's Divi's Labs beats Q3 profit estimates on strong API demand; shares rise	Feb. 03	RE
Divi's Laboratories Limited Appoints Manoranjan Jasti as Chief Information Officer	Feb. 03	CI
Divi's Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	Feb. 03	CI
Divi's Laboratories Limited Announces Commencement of Commercial Operations at Unit III Greenfield Project at Kakinada, Andhra Pradesh in Phased Managed	Jan. 02	CI
Jefferies Adjusts Divi's Laboratories' Price Target to INR5,790 From INR4,830, Keeps at Hold	Nov. 11	MT
Divi's Laboratories Posts Gains in Fiscal Q2 Consolidated Profit	Nov. 11	MT
Divi's Laboratories Limited, Q2 2025 Earnings Call, Nov 09, 2024	Nov. 09
Divi's Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	Nov. 09	CI

Chart Divi's Laboratories Limited

Duration

Period

DIVISLAB: Dynamic Chart

Divi's Laboratories Limited is specialized in the development and manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Net sales by source of revenue break down into product sales (97.9%) and service sales (2.1%). At the end of March 2020, the group has 2 production sites located in India.

Employees

9,741

Sector

Pharmaceuticals

Calendar

Jul. 24 - Détachement de for final dividend

More about the company